An F81 cell line adapted for serum-free suspension culture, its construction method, and its applications
By constructing an F81 cell line adapted to serum-free suspension culture, the problem of limited application in existing technologies has been solved, enabling efficient culture and low-cost production of various vaccine viruses.
Patent Information
- Application Number
- CN202310835337.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-07
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-07-07
AI Technical Summary
The existing F81 cells are only suitable for serum-free suspension culture of a certain virus, which has great limitations in application and the culture effect is generally poor.
F81 cell lines adapted to serum-free suspension culture were constructed. Adherent cells were trained to become F81 cells in serum-free suspension culture, and a monoclonal cell line with high virus yield, F81-04, was screened for application in serum-free suspension production of FCV, FHV, and FPV.
It has achieved efficient culture of three vaccine viruses, FCV, FHV and FPV, significantly improving the culture effect and application scope, reducing production costs, and enabling rapid and stable expansion of production scale.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] This invention relates to the field of veterinary biology, specifically to an F81 cell line adapted for serum-free suspension culture, its construction method, and its application. Background Technology
[0002] Suspension culture technology has been widely used in the biopharmaceutical field and has demonstrated significant advantages. Compared with roller bottle culture, the biggest advantages of suspension culture technology are: First, it increases the number of effective working cells per unit area; second, the fully enclosed, pipelined production process and automated monitoring and control technology not only reduce the chance of cell contamination but also reduce labor intensity and the impact of human operation; third, the increased bioreactor volume improves the uniformity of the final product, and combined with subsequent purification processes, not only significantly increases product yield but also improves product quality; fourth, the labor, workshop, water, electricity, raw materials, and energy costs required for vaccine production are far lower than those of traditional roller bottle culture, resulting in a significant reduction in overall costs.
[0003] Full suspension culture is a carrier-based cell culture process. F81 adherent cells are acclimated to serum-free, fully suspended culture using suspension culture acclimation methods. High-viral-yielding suspension cell lines are then selected and applied to the serum-free, fully suspended production of veterinary FCV, FHV, and FPV, improving antigen production processes and quality while reducing production costs. This method is currently the mainstream model for biopharmaceutical production internationally. Its greatest advantage is that precise and effective process control allows for maximum yield while steadily improving product quality. With the increasing intensification of my country's livestock industry and the expansion of farming scale, low-cost, high-quality vaccines are inevitably needed. Utilizing cell suspension culture technology for vaccine production is an inevitable trend in my country's veterinary biopharmaceutical industry. While some F81 cells adapted to serum-free, fully suspended culture have emerged in existing technologies, these are only suitable for culturing specific viruses, limiting their application and resulting in generally poor culture outcomes. Summary of the Invention
[0004] To address the problems in the existing technology, this invention patent designs an F81 cell line adapted for serum-free full suspension culture and its construction method. This F81 cell line can meet the culture requirements of three vaccine viruses: FCV, FHV, and FPV, and has a high culture yield.
[0005] This invention discloses an F81 cell line adapted for serum-free suspension culture. The F81 cell line is named cat kidney cell F81-04, and is recommended to be classified as cat kidney cell. It was deposited on January 13, 2023 at the China General Microbiological Culture Collection Center, with accession number CGMCC No. 45452.
[0006] Furthermore, the present invention also discloses a method for constructing an F81 cell line adapted for serum-free suspension culture as described above, wherein the construction method comprises the following steps:
[0007] (1) Passaging and culture of adherent cells for preparation:
[0008] The revived F81 cells were cultured in MEM-NEA medium containing 8% fetal bovine serum. When the F81 cells reached a confluent monolayer, an appropriate amount of 0.25% trypsin-EDTA was added and digested at 37°C for 3-5 minutes. When the cells flowed down in a fine sand-like manner, MEM-NEA cell culture medium containing 8% FBS was added to stop the digestion. The adherent cells were pipetted into a suspension and aliquoted into culture flasks at a ratio of 1:3 for passage culture for 2-3 generations.
[0009] (2) Acclimatizing adherent cells to low serum suspension culture medium:
[0010] Take F81 adherent cells that have grown into a monolayer, digest them with an appropriate amount of 0.25% trypsin-EDTA at 37℃ for 3-5 minutes. When the cells start to shrivel and detach, add cell culture medium containing 8% FBS MEM-NEA to stop the digestion, and disperse the cells. Transfer the digested cells to a sterile centrifuge tube, centrifuge at 800 r / min for 5 minutes, and discard the supernatant.
[0011] Resuspend the cells in F806 suspension medium containing 1% FBS, mix well, count the cells, prepare a cell suspension, transfer the cells to a shake flask, and culture them on a shaker in a 37℃, 5% CO2 cell culture incubator at a speed of 140 r / min. Observe and count the cells, and passage them for 2 to 3 generations.
[0012] (3) Acclimatizing cells to a serum-free suspension culture environment:
[0013] F81 cells adapted to low serum culture were seeded into serum-free F806 medium and cultured in an incubator at 37°C and 5% CO2 at a rotation speed of 140 r / min. The cells were passaged every three days until cell growth and status stabilized, thus obtaining serum-free, fully suspended F81 cells.
[0014] (4) Screening of single-clonal cell lines:
[0015] Take 100 μL of 1×10 6F81 cell suspension adapted for serum-free suspension culture was prepared by adding 200 mL of cell growth medium, mixing thoroughly, and then spreading 200 μL into 10 wells of 96-well plates. The 96-well plates were incubated in a CO2 incubator at 37 ± 0.5 °C for 6 days. After observation under a microscope, wells with only one single colony were selected. The selected F81 cell lines were amplified, and cell lines with better growth were inoculated with FCV, FHV, and FPV viruses. A cell line with high production capacity against all three viruses was selected and named cat kidney cell F81-04.
[0016] Furthermore, this invention also discloses the application of the F81 cell line adapted for serum-free suspension culture as described above in the culture of vaccine viruses. The vaccine viruses include FCV, FHV, and FPV.
[0017] Further, the amplification method for the F81 cell line selected in step (4) is as follows: The cell culture medium in the 96-well plate corresponding to the selected monoclonal F81 cell line is aspirated and discarded; the cells are washed twice with PBS to ensure no residual original culture medium or serum remains; EDTA-Tryspin is added dropwise to the selected monoclonal F81 cell line in the 96-well plate, and after addition, the plate is gently shaken to ensure that each cell is in full contact with the EDTA-Tryspin; the container is then placed in a 5% CO2 incubator for digestion for 5-10 minutes; under a microscope, the cells are observed to change from a static spindle shape to a dynamic round shape, indicating that digestion is complete. Simultaneously, fresh cell culture medium is added to the 24-well plate to be amplified, and then the 24-well plate is placed in a 5% CO2 incubator. Preheat the medium in a preheated container. Take a certain amount of cell culture medium from a 24-well plate and transfer it to the digested cells for resuscitation by aspiration and dispersing. Then, aspirate the cell suspension back into the 24-well plate, repeating this process twice to ensure complete cell transfer. Observe the 24-well plate under a microscope to check for cell presence. At this stage, the cells should be dynamic and round. After confirming successful transfer, place the 24-well plate in an incubator for static culture. Once the cells in the 24-well plate have reached confluence, transfer the cells to 6-well plates using the same method. After the cells in the 6-well plates have reached confluence, transfer them to T25 wells using the same method. After the cells in the T25 wells have reached confluence, transfer them to T75 wells using the same method. After the cells in the T75 wells have reached confluence, transfer the cells to a cell shake flask for suspension culture and acclimatization. The cells should be plump, round, clear, and transparent, with a density of 1×10⁶ cells / well. 6 After inoculation with cells / mL, the cells grew to 4-6 × 10⁻⁶ after 3 days. 6 cells / mL, doubling time approximately 30 hours.
[0018] The F81 cell line adapted for serum-free suspension culture disclosed in this invention can be used in the culture of vaccine viruses, with good culture effect and high virus production capacity. The vaccine viruses include FCV, FHV and FPV.
[0019] Furthermore, this invention also discloses a method for culturing F81 cell lines adapted to serum-free full suspension culture for FCV, FHV, and FPV vaccine viruses, as described above. The method involves: inoculating the virus seed into a monolayer of seed adherent cells for production using virus culture medium; harvesting the virus fluid when 80% of the cells show pathogenesis; using this virus fluid as seed virus and the harvested virus fluid as F1 generation seed virus; placing F81-04 cells adapted to serum-free full suspension culture in F806 culture medium and culturing them on a shaker in a 37°C incubator containing 5% CO2 for 72 hours at a shaker speed of 140 r / min until the viability of the F81-04 cell line is >95%, cell growth is stable, and the number of viable cells reaches 4 × 10⁻⁶. 6 After cells / ml, the seed virus was inoculated into the F1 generation at the ratios of FCV, FPV 0.1% (v / v) and FHV 1% (v / v). After 1 hour of adsorption, F806 medium was added as maintenance medium. Then, the cells were placed in an incubator at 37°C with 5% CO2 and cultured at a rotation speed of 140 r / min.
[0020] Compared to existing technologies, the advancement of this invention's F81 cell line adapted for serum-free, fully suspended culture lies in the following: This invention provides a method for serum-free suspension-acclimated F81 adherent cells to become fully suspended F81 cells, and a method for producing vaccine viruses using the acclimated, fully suspended, serum-free F81 cells. Furthermore, the fully suspended, serum-free cultured F81 cells disclosed in this invention can meet the culture requirements of three vaccine viruses: FCV, FHV, and FPV, and the culture effect is significantly improved compared to traditional cell culture methods, resulting in a wider range of applications. Therefore, the serum-free suspension culture of F81 cells provided by this invention for vaccine virus culture can significantly reduce production costs, and can rapidly and stably scale up production, with easily achievable and consistent quality. Detailed Implementation
[0021] The present invention will be further described below with reference to specific embodiments. The technical solutions in the embodiments of the present invention are clearly and completely described. The described embodiments are merely some, not all, of the embodiments created by the present invention. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention.
[0022] The present invention will now be further described in conjunction with specific embodiments:
[0023] Example 1
[0024] During the low serum suspension acclimatization of F81 cells, the MEM-NEA medium and F806 suspension medium used were purchased from Yishengke (Zhejiang) Co., Ltd., and the trypsin was purchased from Gibco.
[0025] After thawing the frozen F81 cells, they were cultured in serum-containing medium, and the F81 cells were acclimatized using a method of gradually reducing serum content. The specific steps included:
[0026] Step 1, Cell resuscitation:
[0027] Remove the frozen F81 adherent cells from the liquid nitrogen tank, shake them rapidly in a 37°C water bath to thaw them quickly, centrifuge at 800 rpm for 5 min, discard the supernatant, resuspend them in an appropriate amount of MEM-NEA cell culture medium containing 8% fetal bovine serum, transfer them into a cell culture flask, and culture them in a 37°C, 5% CO2 incubator until a confluent monolayer is formed.
[0028] Step 2, preparation of adherent cells for passage and culture:
[0029] The revived F81 cells were cultured in MEM-NEA medium containing 8% fetal bovine serum. When the F81 cells reached a confluent monolayer, an appropriate amount of 0.25% trypsin-EDTA was added and digested at 37°C for 3-5 minutes. When the cells flowed down in a fine sand-like manner, MEM-NEA cell culture medium containing 8% FBS was added to stop the process. The adherent cells were pipetted into a suspension and aliquoted into culture flasks at a ratio of 1:3 for passage culture for 2-3 generations.
[0030] Step 3, acclimatizing adherent cells to low serum suspension culture medium:
[0031] Take F81 adherent cells that have grown into a monolayer, digest them with an appropriate amount of 0.25% trypsin-EDTA at 37℃ for 3-5 minutes. When the cells start to shrivel and detach, add cell culture medium containing 8% FBS MEM-NEA to stop the digestion, and disperse the cells. Transfer the digested cells to a sterile centrifuge tube, centrifuge at 800 r / min for 5 minutes, and discard the supernatant.
[0032] Resuspend cells in F806 suspension medium containing 1% FBS, mix well, count, and prepare a cell suspension. Transfer cells to a shake flask and culture on a shaker in a 37℃, 5% CO2 cell culture incubator at 140 rpm. Observe and count cells, and passage for 2-3 generations until the cell density exceeds 2 × 10⁶ cells / min. 6The cells / ml were high, with a viability >95% and stable cell growth, indicating that F81 cells had adapted to low-serum culture medium. The F81 suspension cells adapted to low-serum culture were then passaged multiple times in serum-free F806 medium to obtain F81 suspension cells adapted to serum-free culture.
[0033] Step 4: Passage the F81 cell line for 5 consecutive generations, freeze some cells, and test their biological characteristics according to the current edition of the Chinese Veterinary Pharmacopoeia.
[0034] Step 5, Single-clonal cell line screening:
[0035] Take 200 μL of sample from the shake flask and count the cells using a cell counter. Dilute the sample to 100 cells / well 96-well plate, for example, a count result of 1 × 10⁶ cells / well. 6 cells / mL, take 100μL of cell suspension, i.e., 1×10 5 Dilute 100 μL of the culture medium to 10 mL of adherent culture medium, resulting in a cell density of 1 × 10⁻⁶ cells / 100 μL. 4 Cells / mL: 100 μL of cell suspension equals 1000 cells. Label the 96-well plates to prevent duplicate single-clone names during screening, and label the cell name, culture conditions, operator's name, and operation time. After calculation, aspirate the cell suspension, add 200 mL of cell growth medium, mix thoroughly, and then plate 200 μL into 10 wells of a 96-well plate. Incubate the 96-well plates in a CO2 incubator at 37 ± 0.5 °C for 6 days. Observe under a microscope and screen out wells with only one single colony. Mark the corresponding well on the plate. After marking all wells, return the plates to the incubator and continue static culture until day 10, then proceed with cell expansion. Fifteen monoclonal cell lines were finally selected (F81-01, F81-02, F81-03, F81-04, F81-05, F81-06, F81-07, F81-08, F81-09, F81-10, F81-11, F81-12, F81-13, F81-14, F81-15).
[0036] The cell culture medium from the 15 selected F81 cell lines in 96-well plates was aspirated and discarded. The plates were repeatedly washed with PBS by blowing and aspiration, and then discarded. The plates were washed twice with PBS to ensure that there was no residual original culture medium or serum. EDTA-Tryspin was then added dropwise to the wells. After adding the EDTA-Tryspin, the container was gently shaken to ensure that the cells in each position could fully contact the EDTA-Tryspin. The container was then placed in a 5% CO2 incubator for 10 minutes for digestion. The digestion is complete when the cells change from a static spindle shape to a dynamic round shape under a microscope. Simultaneously, fresh cell culture medium is added to the 24-well plate to be expanded. The 24-well plate is then preheated in a 5% CO2 incubator. After digestion, the 96-well and 24-well plates are simultaneously transferred to a biosafety cabinet. According to the cell names, a certain amount of cell culture medium is aspirated from the 24-well plate and transferred to the digested cells for resuscitation by blowing and aspirating. The cells are then dispersed, and the cell suspension is aspirated back into the 24-well plate. This process is repeated twice to ensure complete cell transfer. The transferred 24-well plate is then placed under a microscope to observe for cells. At this point, the cells are dynamic and round. After confirming successful transfer, the 24-well plate is placed in an incubator for static culture. After the cells in the 24-well plates reached confluence, they were transferred to 6-well plates using the same method. Once the cells in the 6-well plates reached confluence, they were transferred to T25 wells using the same method. After the cells in the T25 wells reached confluence, they were transferred to T75 wells using the same method. Finally, the cells were transferred to shake flasks for suspension culture and acclimatization. The cells were plump, round, clear, and transparent, with a density of 1×10⁶ cells / well. 6 After inoculation with cells / mL, the cells grew to 6×10⁶ cells / mL after 3 days. 6 The cell-to-mL ratio was [number of cells / mL], with a doubling time of approximately 30 hours. Table 1 shows the growth data of 15 F81 cell lines for five consecutive passages in cell culture shake flasks.
[0037] Table 1
[0038]
[0039]
[0040] Based on the growth of 15 F81 cell lines, three cell lines with better growth (F81-04, F81-02, and F81-06) were selected. These three cell lines were then inoculated with FCV, FHV, and FPV virus seeds, respectively, into their fifth-generation cell culture medium, with the cell density controlled at 4.0 × 10⁻⁶. 6 The virus inoculation rate was measured in cells / mL, and the virus production capacity of each cell line was tested. The virus inoculation amount and virus production results of the three cell lines are shown in Table 2.
[0041] Table 2: Inoculation data at the fifth generation of cells
[0042]
[0043] In addition, the three cell lines were passaged to the sixth generation and then inoculated with FCV, FHV, and FPV viruses for secondary validation, with the cell seeding density controlled at 4.0 × 10⁶ cells / year. 6 The cell / mL inoculation amount and harvest results for the three viruses are shown in Table 3.
[0044] Table 3: Inoculation data at the sixth generation of cells
[0045]
[0046]
[0047] After comparison, strain F81-O4 was selected as the final cell line and sent to the China General Microbiological Culture Collection Center for preservation.
[0048] Example 2
[0049] The reagents used in the proliferation and culture methods of FCV, FHV, and FPV in serum-free culture systems
[0050] 1. Viruses: FCV, FHV, and FPV are identified, stored, and supplied by Beijing Dingchi Biotechnology Co., Ltd., and commercially available seed viruses can also be purchased.
[0051] 2. Cells: Fully suspended F81-04 cell line.
[0052] 3. Culture media: The media are named F806 serum-free suspension medium and MEM-NEA medium, supplied by Yishengke (Zhejiang) Co., Ltd.
[0053] Specifically, the steps include the following:
[0054] Step 1, propagation of FCV, FHV, and FPV adherent cell strains:
[0055] FCV, FHV, and FPV strains were inoculated into a monolayer of adherent cells for production seed culture at a certain ratio using viral culture medium. The strains were then harvested when 80% of the cells developed lesions. This strain was used as the seed virus, and the harvested strains were used as the F1 generation of FCV, FHV, and FPV seed virus.
[0056] Step 2, suspension culture of FCV, FHV, and FPV:
[0057] The cat kidney cell line F81-04, obtained by the domestication method described in Example 1, was placed in F806 culture medium and cultured for 72 hours at 37°C on a shaker containing 5% CO2 at a speed of 140 r / min. The culture was continued until the F81 cell viability was >95%, cell growth was stable, and the number of viable cells reached 4 × 10⁻⁶. 6After reaching cell / ml, FCV, FHV, and FPV virus solutions were inoculated at ratios of 0.1%, 1%, and 0.1% (v / v) respectively, followed by passage F1. After 1 hour of adsorption, F806 medium was added as a maintenance medium. The cells were then incubated at 37°C in a 5% CO2 incubator at a rotation speed of 140 rpm. Cells were sampled at 48, 72, and 96 hours after incubation for cell counting, and samples were retained for TCID after 2-3 freeze-thaw cycles. 50 The detection data are shown in Table 4: Count data of three viruses produced by F81-04 cell line at different time points.
[0058]
[0059] The original process potency figures recorded in the table are the results of virus harvesting and testing after culturing commercially available FCV, FHV, and FPV viruses using the original F81 cell line. The test data shows that the three viruses obtained by F81-04 cell culture disclosed in this invention have significantly improved virulence test results compared to viruses obtained by existing F81 cell culture. The F81-04 cells disclosed in this invention can serve as target cells for FCV, FHV, and FPV viruses, enriching the culture and production methods for FCV, FHV, and FPV. Using serum-free culture medium, FCV, FHV, and FPV can be cultured in full suspension in F81-04 cells, greatly improving the scale and efficiency of virus culture. The potency of all three viruses is increased by 1-2 titers compared to the original process, while also reducing production costs, meeting the needs of modern vaccine industrial production. Based on the above advantages, the F81-04 cells disclosed in this invention can be used to culture and prepare whole FCV, FHV, and FPV viruses and to prepare vaccines according to appropriate methods.
[0060] The above description is merely a preferred embodiment of the present invention and should not be construed as limiting the scope of the present invention. Any simple equivalent changes and modifications made in accordance with the claims and description of the present invention shall still fall within the scope of the present invention.
Claims
1. An F81 cell line adapted for serum-free suspension culture, characterized in that, The F81 cell line is named cat kidney cell F81-04, and it is recommended to classify it as cat kidney cell. It was deposited on January 13, 2023, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 45452.
2. The application of the F81 cell line adapted for serum-free suspension culture as described in claim 1 in the culture of vaccine viruses.
3. The application of the F81 cell line adapted for serum-free suspension culture according to claim 2 in the culture of vaccine viruses, characterized in that, The vaccine viruses include FCV, FHV, and FPV.
Citation Information
Patent Citations
Triple vaccine for feline calicivirus infection, feline infectious rhinotracheitis and feline panleukopenia as well as preparation method and application thereof
CN111632137A
Serum-free full-suspension culture type F81 cell line as well as construction method and application thereof
CN114317405A
